KR20220125268A - α4β7 인테그린 길항제를 사용한 염증성 장 질환의 치료 방법 - Google Patents

α4β7 인테그린 길항제를 사용한 염증성 장 질환의 치료 방법 Download PDF

Info

Publication number
KR20220125268A
KR20220125268A KR1020227025943A KR20227025943A KR20220125268A KR 20220125268 A KR20220125268 A KR 20220125268A KR 1020227025943 A KR1020227025943 A KR 1020227025943A KR 20227025943 A KR20227025943 A KR 20227025943A KR 20220125268 A KR20220125268 A KR 20220125268A
Authority
KR
South Korea
Prior art keywords
peptides
pen
lys
methylbenzoyl
glu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020227025943A
Other languages
English (en)
Korean (ko)
Inventor
수닐 쿠마르 굽타
니시트 바출랄 모디
샤올리 쳉
데이비드 와이. 리우
래리 씨. 마테아키스
Original Assignee
프로타고니스트 테라퓨틱스, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 프로타고니스트 테라퓨틱스, 인코포레이티드 filed Critical 프로타고니스트 테라퓨틱스, 인코포레이티드
Publication of KR20220125268A publication Critical patent/KR20220125268A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
KR1020227025943A 2020-01-10 2021-01-08 α4β7 인테그린 길항제를 사용한 염증성 장 질환의 치료 방법 Withdrawn KR20220125268A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062959854P 2020-01-10 2020-01-10
US62/959,854 2020-01-10
PCT/US2021/012842 WO2021142373A1 (en) 2020-01-10 2021-01-08 METHODS FOR TREATING INFLAMMATORY BOWEL DISEASES WITH α4β7 INTEGRIN ANTAGONISTS

Publications (1)

Publication Number Publication Date
KR20220125268A true KR20220125268A (ko) 2022-09-14

Family

ID=76788328

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227025943A Withdrawn KR20220125268A (ko) 2020-01-10 2021-01-08 α4β7 인테그린 길항제를 사용한 염증성 장 질환의 치료 방법

Country Status (11)

Country Link
US (1) US20230063321A1 (enExample)
EP (1) EP4093421A4 (enExample)
JP (2) JP7744910B2 (enExample)
KR (1) KR20220125268A (enExample)
AU (1) AU2021205415B2 (enExample)
BR (1) BR112022013628A2 (enExample)
CA (1) CA3166637A1 (enExample)
IL (1) IL294580A (enExample)
MX (1) MX2022008486A (enExample)
PH (1) PH12022551651A1 (enExample)
WO (1) WO2021142373A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4091624A1 (en) 2013-03-15 2022-11-23 Protagonist Therapeutics, Inc. Hepcidin analogues and uses thereof
CA2949215C (en) 2014-05-16 2023-03-14 Protagonist Therapeutics, Inc. .alpha.4.beta.7 integrin thioether peptide antagonists
SG10201810154WA (en) 2014-07-17 2018-12-28 Protagonist Therapeutics Inc Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
WO2018022937A1 (en) 2016-07-27 2018-02-01 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 and their use to treat inflammatory diseases
WO2019157268A1 (en) 2018-02-08 2019-08-15 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics
CA3104418A1 (en) 2018-07-12 2020-01-16 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
MX2022008740A (es) 2020-01-15 2022-09-23 Janssen Biotech Inc Peptidos inhibidores del receptor de interleucina-23 y su uso para tratar enfermedades inflamatorias.
SMT202500254T1 (it) 2020-01-15 2025-09-12 Janssen Biotech Inc Inibitori peptidici del recettore dell'interleuchina-23 e loro uso per trattare malattie infiammatorie
AU2021383828A1 (en) 2020-11-20 2023-07-06 Janssen Pharmaceutica Nv Compositions of peptide inhibitors of interleukin-23 receptor
KR20240034224A (ko) 2021-07-14 2024-03-13 얀센 바이오테크 인코포레이티드 인터류킨-23 수용체의 지질화된 펩티드 억제제
KR20250084325A (ko) * 2023-12-01 2025-06-11 주식회사 쓰리빅스 염증성 장질환 예방 또는 치료용 약학 조성물

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2013011130A (es) * 2011-03-31 2013-10-30 Genentech Inc Metodos de administracion de antagonistas de integrina beta7.
WO2013078375A2 (en) * 2011-11-23 2013-05-30 Amgen Inc. Administration of alpha4beta7 hetero-dimer-specific antibody
US9273093B2 (en) * 2012-10-11 2016-03-01 Protagonist Therapeutics, Inc. α4β7 peptide dimer antagonists
CA2949215C (en) * 2014-05-16 2023-03-14 Protagonist Therapeutics, Inc. .alpha.4.beta.7 integrin thioether peptide antagonists
JP2017535527A (ja) * 2014-10-01 2017-11-30 プロタゴニスト セラピューティクス， インコーポレイテッド 新規のα４β７ペプチド単量体及び二量体拮抗薬
KR20200015540A (ko) * 2017-05-10 2020-02-12 인사이클 세라퓨틱스, 인코포레이티드 α4β7 인테그린을 타겟팅하는 호모데틱 사이클릭 펩타이드

Also Published As

Publication number Publication date
WO2021142373A1 (en) 2021-07-15
JP2023509790A (ja) 2023-03-09
JP7744910B2 (ja) 2025-09-26
AU2021205415A8 (en) 2023-08-10
IL294580A (en) 2022-09-01
US20230063321A1 (en) 2023-03-02
AU2021205415B2 (en) 2026-06-04
PH12022551651A1 (en) 2023-11-20
CA3166637A1 (en) 2021-07-15
EP4093421A1 (en) 2022-11-30
MX2022008486A (es) 2022-10-13
CN115038457A (zh) 2022-09-09
BR112022013628A2 (pt) 2022-11-22
JP2025186365A (ja) 2025-12-23
EP4093421A4 (en) 2024-01-10
AU2021205415A1 (en) 2022-07-21

Similar Documents

Publication Publication Date Title
JP7744910B2 (ja) α４β７インテグリン拮抗薬で炎症性腸疾患を治療するための方法
US20240209026A1 (en) A4b7 thioether peptide dimer antagonists
US20190099429A1 (en) Cenicriviroc for the treatment of fibrosis
KR20170127021A (ko) 폴리펩티드
CN106999537A (zh) 新颖α4β7肽单体和二聚体拮抗剂
JP2025175999A (ja) 組成物、製剤およびインターロイキンの生成および精製
JP2012505160A (ja) 炎症を処置する方法
KR20120105429A (ko) 염증 치료 방법
EP3617223A1 (en) Application of selective tnfr1 antagonist peptide sn10 in preparation of drugs for preventing and treating rheumatoid arthritis
US20200360347A1 (en) Cenicriviroc for the treatment of fibrosis
TW202114728A (zh) 三重升糖素／ｇｌｐ－１／ｇｉｐ受體促效劑或其接合物用於肝臟疾病之治療用途
CN115335120A (zh) 用于治疗和/或预防冠状病毒诱导的急性呼吸窘迫综合征的抑制masp-2的方法
JP2005537245A5 (ja) プロテイナーゼ活性化レセプターのアンタゴニストを含む組成物および方法
AU2004206842A1 (en) Parenteral formulations of peptides for the treatment of systemic lupus erythematosus
CN108473582A (zh) 用于治疗纤维化和/或纤维化病症的抗－αV整合素抗体
US10905750B2 (en) GRP78 antagonist that block binding of receptor tyrosine kinase orphan receptors as immunotherapy anticancer agents
JP2025506427A (ja) 生物学的製剤の経口送達のための組成物
CN109891237A (zh) 胰岛素制剂的生物测定法
CN120865353B (zh) 一种特异性识别补体C5a的环肽及其制备与用途
US20230382998A1 (en) METHODS FOR TREATING INFLAMMATORY BOWEL DISEASES WITH a4B7 INTEGRIN ANTAGONISTS
WO2021032955A1 (en) Treatment
HK40043191A (zh) 用於心血管疾病的组合治疗

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PC1203 Withdrawal of no request for examination

St.27 status event code: N-1-6-B10-B12-nap-PC1203